{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T22:51:11Z","timestamp":1793141471564,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006694","name":"Associazione Italiana Contro le Leucemie-Linfomi e Mieloma ONLUS","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009703","name":"Fondazione per la Ricerca Biomedica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009703","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009882","name":"Regione Lombardia","doi-asserted-by":"publisher","award":["CP2_10\/2018"],"award-info":[{"award-number":["CP2_10\/2018"]}],"id":[{"id":"10.13039\/501100009882","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012100","name":"Associazione Italiana Contro le Leucemie-Linfomi e Mieloma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012100","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004891","name":"IIlinois State Museum","doi-asserted-by":"publisher","award":["21147"],"award-info":[{"award-number":["21147"]}],"id":[{"id":"10.13039\/100004891","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jcyt.2021.11.004","type":"journal-article","created":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T14:13:58Z","timestamp":1642601638000},"page":"334-343","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use"],"prefix":"10.1016","volume":"24","author":[{"given":"Elisa","family":"Gotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Tettamanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8541-8224","authenticated-orcid":false,"given":"Silvia","family":"Zaninelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Cuofano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5094-7150","authenticated-orcid":false,"given":"Irene","family":"Cattaneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3214-1540","authenticated-orcid":false,"given":"Maria Caterina","family":"Rotiroti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Cribioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachele","family":"Alzani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6216-0892","authenticated-orcid":false,"given":"Martino","family":"Introna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9e","family":"Golay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jcyt.2021.11.004_bib0001","first-page":"1253","article-title":"Innovative cell-based therapies in onco-hematology: what are the clinical facts ?","volume":"89","author":"Introna","year":"2004","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.jcyt.2021.11.004_bib0002","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3390\/cancers13040743","article-title":"Adoptive Immunotherapy beyond CAR T-Cells","volume":"13","author":"Titov","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.jcyt.2021.11.004_bib0003","doi-asserted-by":"crossref","first-page":"952","DOI":"10.3324\/haematol.11132","article-title":"Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study","volume":"92","author":"Introna","year":"2007","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.jcyt.2021.11.004_bib0004","first-page":"2070","article-title":"Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation","volume":"23","author":"Introna","year":"2017","journal-title":"BBMT"},{"key":"10.1016\/j.jcyt.2021.11.004_bib0005","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jaut.2017.06.008","article-title":"CIK as therapeutic agents against tumors","volume":"85","author":"Introna","year":"2017","journal-title":"Journal of Autoimmunity"},{"issue":"7","key":"10.1016\/j.jcyt.2021.11.004_bib0006","first-page":"1281","article-title":"Clearance of Hematologic Malignancies by Allogeneic Cytokine-Induced Killer Cell or Donor Lymphocyte Infusions","volume":"25","author":"Merker","year":"2019","journal-title":"BBMT"},{"issue":"9","key":"10.1016\/j.jcyt.2021.11.004_bib0007","doi-asserted-by":"crossref","first-page":"4739","DOI":"10.4049\/jimmunol.1401550","article-title":"A novel method using blinatumomab for efficient, clinical-grade expansion of polyclonal T cells for adoptive immunotherapy","volume":"193","author":"Golay","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.jcyt.2021.11.004_bib0008","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/434392","article-title":"Optimization manufacture of virus- and tumor-specific T cells","author":"Lapteva","year":"2011","journal-title":"Stem Cells Int. 2011"},{"issue":"1","key":"10.1016\/j.jcyt.2021.11.004_bib0009","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s13036-021-00264-7","article-title":"Lymphocyte expansion in bioreactors: upgrading adoptive cell therapy","volume":"15","author":"Garcia-Aponte","year":"2021","journal-title":"J. Biol. Eng"},{"issue":"4","key":"10.1016\/j.jcyt.2021.11.004_bib0010","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.cbpa.2007.05.034","article-title":"Bioreactor development for stem cell expansion and controlled differentiation","volume":"11","author":"King","year":"2007","journal-title":"Curr. Op Chem. Biol."},{"key":"10.1016\/j.jcyt.2021.11.004_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2021.107735","article-title":"Objectives, benefits and challenges of bioreactor systems for the clinical-scale expansion of T lymphocyte cells","volume":"49","author":"Baudequin","year":"2021","journal-title":"Biotech. Advances"},{"issue":"3","key":"10.1016\/j.jcyt.2021.11.004_bib0012","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/CJI.0b013e3181c0c3cb","article-title":"Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)","volume":"33","author":"Vera","year":"2010","journal-title":"J. Immunother."},{"key":"10.1016\/j.jcyt.2021.11.004_bib0013","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-0716-0146-4_12","article-title":"Methods and Process Optimization for Large-Scale CAR T Expansion Using the G-Rex Cell Culture Platform","volume":"2086","author":"Ludwig","year":"2020","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jcyt.2021.11.004_bib0014","doi-asserted-by":"crossref","first-page":"14015","DOI":"10.1038\/mtm.2014.15","article-title":"Optimizing the production of suspension cells using the G-Rex \"M\" series, Molecular therapy","volume":"1","author":"Bajgain","year":"2014","journal-title":"Methods & Clin. Dev."},{"issue":"9","key":"10.1016\/j.jcyt.2021.11.004_bib0015","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.3109\/14653249.2012.700767","article-title":"Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications","volume":"14","author":"Lapteva","year":"2012","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.jcyt.2021.11.004_bib0016","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/j.jcyt.2019.10.006","article-title":"StreamLined production of genetically modified T cells with activation, transduction and expansion in closed-system G-Rex bioreactors","volume":"21","author":"Gagliardi","year":"2019","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jcyt.2021.11.004_bib0017","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.omtm.2018.12.010","article-title":"In Vitro Expansion of Anti-viral T Cells from Cord Blood by Accelerated Co-cultured Dendritic Cells","volume":"13","author":"Kuranda","year":"2019","journal-title":"Molecular therapy. Methods & Clin. Dev."},{"issue":"51","key":"10.1016\/j.jcyt.2021.11.004_bib0018","first-page":"e2736","article-title":"Generation of multivirus-specific T cells to prevent\/treat viral infections after allogeneic hematopoietic stem cell transplant","author":"Gerdemann","year":"2011","journal-title":"JoVE"},{"issue":"3","key":"10.1016\/j.jcyt.2021.11.004_bib0019","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/CJI.0b013e31824e801f","article-title":"Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment","volume":"35","author":"Jin","year":"2012","journal-title":"J. Immunother."},{"issue":"2","key":"10.1016\/j.jcyt.2021.11.004_bib0020","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1057386","article-title":"The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity","volume":"5","author":"Forget","year":"2016","journal-title":"Oncoimmunology"},{"issue":"4","key":"10.1016\/j.jcyt.2021.11.004_bib0021","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3324\/haematol.2012.076430","article-title":"Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease","volume":"98","author":"Chakraborty","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.jcyt.2021.11.004_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fimmu.2019.00038","article-title":"Automated Clinical Grade Expansion of Regulatory T Cells in a Fully Closed System","volume":"10","author":"Marin Morales","year":"2019","journal-title":"Front. Immunol."},{"issue":"3","key":"10.1016\/j.jcyt.2021.11.004_bib0023","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.jcyt.2017.12.014","article-title":"Large-scale expansion of Vgamma9Vdelta2 T cells with engineered K562 feeder cells in G-Rex vessels and their use as chimeric antigen receptor-modified effector cells","volume":"20","author":"Xiao","year":"2018","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2021.11.004_bib0024","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jcyt.2015.05.013","article-title":"Low-cost generation of Good Manufacturing Practice-grade CD19-specific chimeric antigen receptor-expressing T cells using piggyBac gene transfer and patient-derived materials","volume":"17","author":"Ramanayake","year":"2015","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2021.11.004_bib0025","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jcyt.2020.05.003","article-title":"A serum-free protocol for the ex vivo expansion of Cytokine-Induced Killer cells using gas-permeable static culture flasks","volume":"22","author":"Palmerini","year":"2020","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.jcyt.2021.11.004_bib0026","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1182\/blood-2010-06-290858","article-title":"Enhanced killing of human B-cell lymphoma targets by combined use of cytokine-induced killer cell (CIK) cultures and anti-CD20 antibodies","volume":"117","author":"Pievani","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2021.11.004_bib0027","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.exphem.2010.02.004","article-title":"Therapeutic efficacy of the pan-cdk inhibitor PHA-793887 in vitro and in vivo in engraftment and high-burden leukemia models","volume":"38","author":"Alzani","year":"2010","journal-title":"Exp. Hematol."},{"issue":"8","key":"10.1016\/j.jcyt.2021.11.004_bib0028","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.jcyt.2018.06.003","article-title":"Cord blood-derived cytokine-induced killer cells combined with blinatumomab as a therapeutic strategy for CD19(+) tumors","volume":"20","author":"Golay","year":"2018","journal-title":"Cytotherapy"},{"issue":"9","key":"10.1016\/j.jcyt.2021.11.004_bib0029","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.yexcr.2011.03.010","article-title":"Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab","volume":"317","author":"Nagorsen","year":"2011","journal-title":"Exp. Cell Res."},{"issue":"9","key":"10.1016\/j.jcyt.2021.11.004_bib0030","first-page":"621","article-title":"Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation","volume":"38","author":"Introna","year":"2006","journal-title":"BMT"},{"key":"10.1016\/j.jcyt.2021.11.004_bib0031","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1007\/978-1-0716-0146-4_11","article-title":"CAR-T Cell Expansion in a Xuri Cell Expansion System W25","volume":"2086","author":"Smith","year":"2020","journal-title":"Methods Mol.Biol"},{"issue":"6","key":"10.1016\/j.jcyt.2021.11.004_bib0032","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1182\/blood-2007-06-092817","article-title":"In vivo trafficking and survival of cytokine-induced killer cells resulting in minimal GVHD with retention of antitumor activity","volume":"112","author":"Nishimura","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2021.11.004_bib0033","doi-asserted-by":"crossref","first-page":"271","DOI":"10.3389\/fimmu.2020.00271","article-title":"Characterization of a Cytomegalovirus-Specific T Lymphocyte Product Obtained Through a Rapid and Scalable Production Process for Use in Adoptive Immunotherapy","volume":"11","author":"Grau-Vorster","year":"2020","journal-title":"Front. Immunol."},{"issue":"8","key":"10.1016\/j.jcyt.2021.11.004_bib0034","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/mt.2012.130","article-title":"Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infections","volume":"20","author":"Gerdemann","year":"2012","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.jcyt.2021.11.004_bib0035","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jcyt.2014.12.009","article-title":"Early exposure to interleukin-21 limits rapidly generated anti-Epstein-Barr virus T-cell line differentiation","volume":"17","author":"Orio","year":"2015","journal-title":"Cytotherapy"},{"issue":"7","key":"10.1016\/j.jcyt.2021.11.004_bib0036","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1002\/sctm.18-0160","article-title":"Enabling Large-Scale Ex Vivo Production of Megakaryocytes from CD34(+) Cells Using Gas-Permeable Surfaces","volume":"8","author":"Martinez","year":"2019","journal-title":"Stem Cells Transl. Med"},{"issue":"21","key":"10.1016\/j.jcyt.2021.11.004_bib0037","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1182\/bloodadvances.2019000689","article-title":"Large-scale in vitro production of red blood cells from human peripheral blood mononuclear cells","volume":"3","author":"Heshusius","year":"2019","journal-title":"Blood advances"},{"issue":"8","key":"10.1016\/j.jcyt.2021.11.004_bib0038","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1182\/blood-2015-06-653667","article-title":"Umbilical cord blood-derived T regulatory cells to prevent GVHD: kinetics, toxicity profile, and clinical effect","volume":"127","author":"Brunstein","year":"2016","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jcyt.2021.11.004_bib0039","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/14712598.2017.1316713","article-title":"Advances in umbilical cord blood cell therapy: the present and the future","volume":"17","author":"Berglund","year":"2017","journal-title":"Exp. Op. Biol. Ther."},{"issue":"Suppl 3","key":"10.1016\/j.jcyt.2021.11.004_bib0040","article-title":"New emerging targets in cancer immunotherapy: CD27 (TNFRSF7)","volume":"4","author":"Starzer","year":"2020","journal-title":"ESMO open"},{"issue":"1","key":"10.1016\/j.jcyt.2021.11.004_bib0041","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1182\/blood-2017-07-741025","article-title":"The immunobiology of CD27 and OX40 and their potential as targets for cancer immunotherapy","volume":"131","author":"Buchan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jcyt.2021.11.004_bib0042","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-981-32-9717-3_2","article-title":"The CD28-B7 Family of Co-signaling Molecules","volume":"1189","author":"Nagai","year":"2019","journal-title":"Advances in Exp. Med & Biol."},{"issue":"5","key":"10.1016\/j.jcyt.2021.11.004_bib0043","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.exphem.2009.01.010","article-title":"Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes","volume":"37","author":"Franceschetti","year":"2009","journal-title":"Exp. Hematol."}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921008872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324921008872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T01:46:38Z","timestamp":1761443198000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324921008872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1465324921008872"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.11.004","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimization of therapeutic T cell expansion in G-Rex device and applicability to large-scale production for clinical use","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2021.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 International Society for Cell &#38; Gene Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}